DPP4 and hydrops fetalis: A recent comprehensive systematic review and meta-analysis of 114 randomized trials including 107 100 patients demonstrated that DPP4 inhibitors did not affect all-cause mortality (RR 1.01, 95% CI 0.94–1.09), CV mortality (RR 0.98, 95% CI 0.89–1.07), incident MI, stroke or HF.70